Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILT-123 + Pembrolizumab +/- PLD in Platinum Resistant/Refractory Ovarian Cancer
NCT05271318Phase 2Active, not recruiting
- Sponsor
- TILT Biotherapeutics
- Start
- May 2022
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 2, open-label trial of Ad5/3-E2F-D24 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by TILT Biotherapeutics. Primary endpoints: Number of Participants with any (serious and non-serious) Adverse Events at Day 92, Number of Participants with vital sign abnormalities at Day 92 and 2 more. Started May 2022; status: active, not recruiting.
02
Drugs
Ad5/3-E2F-D24
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05271318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271318.